Table 3.

Efficacy of different subgroup in CG

	C(n = 29)	AC(n = 31)	IC(n = 16)	AIC(n = 15)
ORR	20.7%	38.7%	25%	53.3%
PFS(m,95% CI)	3.4(2.3–4.5)	5.1(3.5–6.6)	5.5(2.7–8.2)	6.4(5.7–7.1)

CG Chemotherapy group, C Chemotherapy alone subgroup, AC Anti-angiogenesis plus chemotherapy subgroup, IC Immune checkpoint inhibitors plus chemotherapy subgroup, AIC A combination of immune checkpoint inhibitors, anti-angiogenesis and chemotherapy subgroup, ORR Objective response rate, PFS Progression-free survival, CI Confidence interval